Skip to main content
SpringerLink
Log in

Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239–1247

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Yoshino K, Kamiura S, Yokoi T, Nakae R, Fujita M, Takemura M, Adachi K, Wakimoto A, Nishizaki T, Shiki Y, Tsutsui T, Kanda Y, Kobayashi E, Hashimoto K, Mabuchi S, Ueda Y, Sawada K, Tomimatsu T, Kimura T (2017) Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol 80(6):1239–1247. https://doi.org/10.1007/s00280-017-3468-5 (Epub 2017 Oct 28)

    Article  PubMed  CAS  Google Scholar 

  2. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W (2008) Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 26(19):3176–3182. https://doi.org/10.1200/JCO.2007.15.1258

    Article  PubMed  CAS  Google Scholar 

  3. Goff BA, Holmberg LA, Veljovich D, Kurland BF, Puget Sound Oncology Consortium (2008) Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. Gynecol Oncol 110(2):146–151. https://doi.org/10.1016/j.ygyno.2008.04.037 (Epub 2008 Jun 6)

    Article  PubMed  CAS  Google Scholar 

  4. Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K, Ochiai K (2013) Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study. Int J Clin Oncol 18(1):126–131. https://doi.org/10.1007/s10147-011-0353-9 (Epub 2011 Nov 30)

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Gynecologic Oncology, HELIOS Dr. Horst-Schmidt-Kliniken Wiesbaden, Ludwig-Erhard-Str. 100, 65199, Wiesbaden, Germany

    Michael Eichbaum

  2. Department of Obstetrics and Gynecology, Klinikum Darmstadt, Darmstadt, Germany

    Christine Eichbaum

Authors
  1. Michael Eichbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine Eichbaum
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Eichbaum.

Ethics declarations

Conflict of interest

The authors declare that there is no conflict of interest for both of the authors.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eichbaum, M., Eichbaum, C. Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239–1247. Cancer Chemother Pharmacol 82, 1087–1088 (2018). https://doi.org/10.1007/s00280-018-3589-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-018-3589-5

Search

Navigation